Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
|Videos|August 27, 2021
IVGE process and optimization
Author(s)Roche
Advertisement
In vitro glycoengineering (IVGE) works by modifying glycosylation enzymatically after proteins are harvested. A specific sugar is linked to a compatible N-glycan backbone in a straightforward and scalable cell-free enzyme reaction. IVGE therefore separates terminal glycosylation from depending on cellular function during fermentation. Watch to learn more about the process and optimization of IVGE reactions.
Advertisement
Related to this article
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
A single subcutaneous dose of Janux’s CD19-targeted T-cell engager JANX011 depleted more than 90% of B cells in three of five healthy volunteers at the top dose, with only Grade 1 cytokine release syndrome. Patient studies in immune thrombocytopenia and rheumatoid arthritis are planned for 2027.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
In a phase 1 study, Johnson & Johnson’s combination of pasritamig and JNJ-9401, two bispecific antibodies targeting KLK2 and PSMA, cut PSA by at least 50% in 73% of patients with metastatic castration-resistant prostate cancer. The regimen is now in phase 3.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
5